Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This acquisition solidifies Candel’s viral therapy leadership position and supports further development of Candel’s rQNestin34.5, currently in a Phase 1 study for recurrent malignant gliomas.
Lead Product(s): rQNestin34.5
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Candel Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 08, 2020